Clinical Trials Directory

Trials / Terminated

TerminatedNCT01689506

Fluid Resuscitation in Patients Suffering From Burns Injury

Prospective Randomised Controlled Open-label Explorative Multi-centre Pilot Trial of Volulyte®-Supplemented Versus Albumin-supplemented Fluid Resuscitation for Major Burns

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
11 (actual)
Sponsor
Fresenius Kabi · Industry
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This clinical study compares two fluid resuscitation treatments in patients suffering from burns injury. The treatments are Volulyte® and Human Serum Albumin (HSA) which will be administered as infusion solutions. It will be evaluated whether Volulyte® is effective and safe, and provides any benefit.

Detailed description

Severe burns injury presents a unique resuscitation problem due to simultaneous loss of electrolyte and protein-rich exudate from the burn wound itself and leakage of fluid and protein from the circulation into the interstitial compartment. In the post shock phase of burn resuscitation, patients frequently suffer oedema of unburned tissues and organs and a positive fluid balance of many litres. This pilot study will compare two burns fluid resuscitation regimes (supplementation with 6% HES 130/0.4 in an isotonic electrolyte solution, Volulyte 6%, versus supplementation with Human Serum Albumin, HSA 50g/L) on patient outcome with particular regard to fluid balance at 24 hours after burns injury (primary variable).

Conditions

Interventions

TypeNameDescription
DRUGVolulyte6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution will be intravenously infused in order to achieve and maintain predefined hemodynamics goals and may be given up to a total daily dose of 50 mL/kg body weight/day.
DRUGHuman Serum Albumin5% Human Serum Albumin will be intravenously infused in order to achieve and maintain predefined hemodynamics goals with no daily dose limit.

Timeline

Start date
2012-12-01
Primary completion
2013-09-01
Completion
2013-09-01
First posted
2012-09-21
Last updated
2014-06-26

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT01689506. Inclusion in this directory is not an endorsement.